Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Hamidi, T. Abdel-Razek, A. Szema, S. Said (Stony Brook, NY, Northport, NY, United States Of America). In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy. Eur Respir J 2007; 30: Suppl. 51, 223

Member's Comments

No comment yet.

Related content which might interest you: Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2013; 41: 224-232 Year: 2013 Involvement of FHL1 in vascular remodelling Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension Source: Annual Congress 2005 - Scientific year in review Year: 2005 Pulmonary hypertension: the science behind the disease spectrum Source: Eur Respir Rev 2012; 21: 19-26 Year: 2012 Molecular determinants of cardiac and pulmonary vascular remodeling in scleroderma-related pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension in connective tissue diseases Year: 2008 The pathobiology and genetics of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011 Contribution of angiopoietin/Tie2 pathway to pulmonary artery smooth muscle hyperplasia in idiopathic pulmonary hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition Source: Eur Respir J 2008; 31: 599-610 Year: 2008 PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Effects of erythropoietin on advanced pulmonary vascular remodelling Source: Eur Respir J 2008; 31: 126-134 Year: 2008 Chronic thromboembolic pulmonary hypertension: animal models Source: Eur Respir J 2013; 41: 1200-1206 Year: 2013 Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 The unknown pathophysiological relevance of right ventricular hypertrophy in pulmonary arterial hypertension Source: Eur Respir J, 53 (4) 1900255; 10.1183/13993003.00255-2019 Year: 2019 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Carvedilol partially reverses maladaptive remodeling and improves function of the right ventricle (RV) in experimentally-induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Pulmonary hypertension in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 892-905 Year: 2003 Mast cells promote lung vascular remodelling in pulmonary hypertension Source: Eur Respir J 2011; 37: 1400-1410 Year: 2011